Donor-specific antibodies, C4d and their relationship with the prognosis of transplant glomerulopathy

Transplantation

Volumn 99, Issue 1, 2015, Pages 69-76

  Lesage, Julie ^a   Noël, Réal ^a   Lapointe, Isabelle ^a   Côté, Isabelle ^a   Wagner, Eric ^b   Désy, Olivier ^a   Caumartin, Yves ^a   Agharazii, Mohsen ^a   Batal, Ibrahim ^c   Houde, Isabelle ^a   De Serres, Sacha A ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C4D; CREATININE; DONOR SPECIFIC ANTIBODY; IMMUNOGLOBULIN G; METHYLPREDNISOLONE SODIUM SUCCINATE; UNCLASSIFIED DRUG; ALLOANTIBODY; BIOLOGICAL MARKER; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; PEPTIDE FRAGMENT;

ADULT; ALLOIMMUNITY; ANTIBODY MEDIATED REJECTION; ARTICLE; CHRONIC GRAFT REJECTION; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GLOMERULOPATHY; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLASMAPHERESIS; PROGNOSIS; PROTEINURIA; RENAL GRAFT DYSFUNCTION; RETROSPECTIVE STUDY; TRANSPLANT GLOMERULOPATHY; BLOOD; CHRONIC DISEASE; DISEASE COURSE; GRAFT REJECTION; IMMUNOLOGY; KIDNEY; KIDNEY TRANSPLANTATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; TIME; TREATMENT OUTCOME;

ADULT; BIOLOGICAL MARKERS; CHRONIC DISEASE; COMPLEMENT C4B; CREATININE; DISEASE PROGRESSION; FEMALE; GRAFT REJECTION; HUMANS; ISOANTIBODIES; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84920284397     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000310     Document Type: Article

References (33)

1. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007;7:518.
2. Cosio FG, Gloor JM, Sethi S, et al. Transplant glomerulopathy. Am J Transplant 2008;8:492.
3. Cosio FG, Grande JP, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005;5:2464.
4. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007;7:2124.
5. Maryniak RK, First MR, Weiss MA. Transplant glomerulopathy: evolution of morphologically distinct changes. Kidney Int 1985;27:799.
6. Suri DL, Tomlanovich SJ, Olson JL, et al. Transplant glomerulopathy as a cause of late graft loss. Am J Kidney Dis 2000;35:674.
7. Banfi G, Villa M, Cresseri D, et al. The clinical impact of chronic transplant glomerulopathy in cyclosporine era. Transplantation 2005;80:1392.
8. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007;7:1743.
9. Kieran N, Wang X, Perkins J, et al. Combination of peritubular c4d and transplant glomerulopathy predicts late renal allograft failure. J Am Soc Nephrol 2009;20:2260.
10. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007;18:1046.
11. Baid-Agrawal S, Farris AB 3rd, Pascual M, et al. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 2011;80:879.
12. Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003;75:1034.
13. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004;4:438.
14. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16:2804.
15. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012;12:1157.
16. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009;9:2561.
17. MengelM, Sis B, HaasM, et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012;12:563.
18. Smith RN, Kawai T, Boskovic S, et al. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant 2008;8:1662.
19. De Serres SA, Vadivel N,Mfarrej BG, et al.Monocyte-secreted inflammatory cytokines are associated with transplant glomerulopathy in renal allograft recipients. Transplantation 2011;91:552.
20. Akalin E, Dinavahi R, Dikman S, et al. Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. Clin J Am Soc Nephrol 2007;2:1261.
21. Hayde N, Bao Y, Pullman J, et al. The clinical and genomic significance of donor-specific antibody-positive/C4d-negative and donor-specific antibody-negative/C4d-negative transplant glomerulopathy. Clin J Am Soc Nephrol 2013;8:2141.
22. Sis B, Jhangri GS, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009;9:2312.
23. Akalin E, Dikman S, Murphy B, et al. Glomerular infiltration by CXCR3+ ICOS+ activated T cells in chronic allograft nephropathy with transplant glomerulopathy. Am J Transplant 2003;3:1116.
24. Batal I, De Serres SA,MfarrejBG, et al. Glomerular inflammation correlates with endothelial injury and with IL-6 and IL-1beta secretion in the peripheral blood. Transplantation 2014;97:1034.
25. Tinckam KJ, Djurdjev O, Magil AB. Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. Kidney Int 2005;68:1866.
26. Lenihan CR, Tan JC, Kambham N. Acute transplant glomerulopathy with monocyte rich infiltrate. Transpl Immunol 2013;29:114.
27. Bloom D, Chang Z, Pauly K, et al. BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant 2009; 9:1835.
28. Chhabra D, Alvarado A, Dalal P, et al. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisonefree regimen. Am J Transplant 2013;13:2902.
29. Lebranchu Y, Thierry A, Thervet E, et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF - four-year results of the Postconcept study. Am J Transplant 2011;11:1665.
30. Bluestone JA, Auchincloss H, Nepom GT, et al. The immune tolerance network at 10 years: tolerance research at the bedside. Nat Rev Immunol 2010;10:797.
31. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009;9:1099.
32. Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibodymediated rejection in kidney transplant recipients - a systematic review. Transplantation 2012;94:775.
33. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008;8:753.